-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OtIVN5/4Dn4PXq6mJDDJcqq1Jnhojn4pNLTiESzo+HLhG/paSqFCKrFejPpWUeMK UqQvdUzQNQN0NH+fWOBAnA== 0001250853-09-000030.txt : 20090413 0001250853-09-000030.hdr.sgml : 20090413 20090413145905 ACCESSION NUMBER: 0001250853-09-000030 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20090413 DATE AS OF CHANGE: 20090413 EFFECTIVENESS DATE: 20090413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-94096 FILM NUMBER: 09746477 BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 D/A 1 primary_doc.xml X0301 D/A LIVE 0001335105 LIXTE BIOTECHNOLOGY HOLDINGS, INC. 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 631-942-7959 SRKP 7 INC DE Corporation true 2005 John S. Kovach 248 Route 25A No. 2 East Setauket NY 11733 Executive Officer Director Stephen K. Carter 248 Route 25A No. 2 East Setauket NY 11733 Director Philip F. Palmedo 248 Route 25A No. 2 East Setauket NY 11733 Director Mel Sorenson 248 Route 25A No. 2 East Setauket NY 11733 Director Biotechnology No Revenues 06 true 9999999997-09-004895 2009-02-10 false true false 0 None None WestPark Capital, Inc. 39914 1900 Avenue of the Stars, Suite 310 Los Angeles CA 90067 AR CA DC FL GA MA MI MS NH NJ NY OH PA TX UT WI 2000000 710000 1290000 false 28 71000 28400 *Plus 5 year warrants to purchase 142,000 shares of Issuer's Common Stock and 5 year warrants to purchase an additional 28,400 shares. 0 false LIXTE BIOTECHNOLOGY HOLDINGS, INC. /s/ John S. Kovach John S. Kovach Chief Executive Officer 2009-04-10 -----END PRIVACY-ENHANCED MESSAGE-----